Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, SVY

Ultromics Lauded by Frost & Sullivan for Pioneering AI-based Cardiovascular Suite, EchoGo


The SaaS suite helps physicians automate key measurements and predict the occurrence of CAD, enabling clinicians to proactively recommend preventive actions that improve patient outcomes

LONDON, Sept. 24, 2020 /CNW/ -- Based on its recent analysis of the global AI-based echocardiography market, Frost & Sullivan recognizes Ultromics with the 2020 Global New Product Innovation Award for enhancing diagnostic quality in cardiac care units with its AI suite, EchoGo. The FDA and CE-cleared solutions (respectively EchoGo Core and EchoGo Pro) not only automate measurements for heart functions but also empower physicians to predict the occurrence of coronary artery disease (CAD). With a cloud-based Software-as-a-Service (SaaS) format, they enable quick deployment, minimal training, and hassle-free upgrades.

Click here to download the full report: https://ultromics.com/best-practices-award/

"Ultromics' EchoGo Core performs cardiac measurements, including ejection fraction (EF), global longitudinal strain (GLS), left ventricular (LV) volume, and myocardial strain reporting. By automating these measurements, Ultromics eases one of the most tedious steps in cardiovascular conditions' diagnosis, thus saving time and removing inter-operator variability," said Parth Shah Research Analyst. "Meanwhile, EchoGo Pro serves as a clinical decision support tool for physicians by assessing the risk profiles of patients. As an industry-first solution within cardiac echocardiography, it enables early detection and prevention of CAD supported by evidence at the point of care."

Furthermore, being a cloud-based solution, it can be delivered as a SaaS model, which allows deployments to be completed faster than with traditional PACS software integrations. The SaaS model also does away with the need for future upgrades, patches, and associated fees. The solution is designed to be intuitive, minimizing the need for substantial user training required by other solutions. Once usage begins, it employs a zero-click, off-the-cart usage approach, eliminating the need for users to manually upload or cross-launch scans.

Being a vendor-neutral solution, Ultromics can target any provider, regardless of the echocardiography equipment they use, across regions. While the EchoGo solutions are currently available in the western markets, Ultromics will target the Asia-Pacific market in the future. Its adoption in developed markets received a major boost in 2020 when the Strain procedure obtained a CPT code that allows physicians to report and bill myocardial strain diagnosis. It is also one of the very few AI solutions in the imaging space to qualify for reimbursement.

"EchoGo's pricing structure delivers significant return on investment with no upfront costs. While competitors offer comparable price points, their need for additional software upgrades and associated installation costs and efforts make them more expensive in the long term. Ultromics adopts a pay-per-use pricing model but can also offer a subscription model depending on the volume of procedures being conducted," noted Shah. "EchoGo automates the entire process, allowing physicians to save on costs while having zero user interactions to obtain results. Overall, Ultromics' price-value proposition helps it capture a larger share of the market and positions it for continued growth globally."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Harley Gadomski
P: 12104778469
E: harley.gadomski@frost.com

About Ultromics

Ultromics is a global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. EchoGo, the world's first autonomous echocardiography service provides cloud-based artificial intelligence services to support cardiac imaging diagnosis without any variability or need to touch software. Our technology was born at the University of Oxford and built in partnership with the NHS, and has since raised over £20 million to help improve patient care, and bring diagnostic quality and resource savings to hospitals. Cardiovascular disease is the leading cause of mortality, with an estimated 17 million deaths each year. www.ultromics.com

CONTACT:       
Kyle Souligne
Director of Marketing - Ultromics
Kyle.Souligne@Ultromics.com 

SOURCE Frost & Sullivan


These press releases may also interest you

at 02:35
Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and...

at 02:35
Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the detailed results from the Phase 1b/2 trial combining TG4001, a...

at 02:25
Tecan to expand U.S. pipette tip manufacturing for COVID-19 testing supported through a $32.9 million investment by the U.S. Government New U.S. manufacturing lines expected to start pipette tip production in fall 2021Additionally, Tecan has...

at 02:00
The Virtual HIPAA Privacy and Security Summit is a joint effort of Delaware Law School and First Healthcare Compliance to provide resources for attorneys and professionals facing the challenges of HIPAA compliance. The online event will be held on...

at 01:05
Exelixis, Inc. today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono), have...

at 00:05
The biodefense market is poised to grow by USD 3.22 billion during 2020-2024 progressing at a CAGR of over 8% during the forecast period. The report on the biodefense market provides a holistic update, market size and forecast, trends, growth...



News published on 24 september 2020 at 13:48 and distributed by: